Literature DB >> 311784

Mechanism of inhibition of porcine elastase by human alpha-1-antitrypsin.

H L James, A B Cohen.   

Abstract

The interaction of the human plasma protein, alpha-1-antitrypsin, with porcine pancreatic elastase was studied by isolating and characterizing their reaction products. Native alpha-1-antitrypsin has a mass ratio (Mr) of 54,000, an amino-terminal glx, and a carboxy-terminal lys residue. The elastase used has an Mr of 26,400 and an amino-terminal val residue. When the two proteins are combined at inhibitor excess, two major products result. One of the products is a complex of the enzyme and inhibitor with amino-terminal ser and val residues, which indicates that a peptide has been removed from the amino-terminal end of the inhibitor. The second product is a modified form of alpha-1-antitrypsin with an Mr of 51,300, an aminoterminal glx residue and a carboxy-terminal thr-leu dipeptide. It has no inhibitory activity against elastase. The components of the isolated complex can be split at high pH in the presence of diisopropyl fluorophosphate, which results in a catalytically inactive enzyme with the same Mr and amino-terminal residue as the native enzyme, and a large fragment of alpha-1-antitrypsin (alpha-1-antitrypsin(*)). This fragment has an Mr of 50,100, an amino-terminal ser residue and a carboxy-terminal thr-leu dipeptide. Based on these data, the following hypothesis is proposed. Elastase can attack alpha-1-antitrypsin at either of two major sites. If it attacks first at the carboxy side of the thr-leu dipeptide, located in the carboxy-terminal portion of the inhibitor, the alpha-1-antitrypsin is cleaved into two fragments with loss of inhibitory activity and absence of complex formation. If, however, the elastase first attacks an x-ser bond near the amino-terminal end of the inhibitor, the elastase then reacts with alpha-1-antitrypsin at the same leu moiety to form a stable complex with complete inhibition of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 311784      PMCID: PMC371900          DOI: 10.1172/JCI109255

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Carboxypeptidase Y.

Authors:  R Hayashi
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  On the mechanism of enzyme action. 73. Studies on trypsins from beef, sheep and pig pancreas.

Authors:  F F BUCK; A J VITHAYATHIL; M BIER; F F NORD
Journal:  Arch Biochem Biophys       Date:  1962-05       Impact factor: 4.013

4.  Purification and specificity of pancreatic elastase.

Authors:  M A NAUGHTON; F SANGER
Journal:  Biochem J       Date:  1961-01       Impact factor: 3.857

5.  IN VIVO BEHAVIOR OF I-FIBRINOGEN.

Authors:  A S McFarlane
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

6.  Elastase release from human alveolar macrophages: comparison between smokers and nonsmokers.

Authors:  R J Rodriguez; R R White; R M Senior; E A Levine
Journal:  Science       Date:  1977-10-21       Impact factor: 47.728

7.  Rapid inactivation of alpha1-protease inhibitor (alpha1-antitrypsin) by elastase.

Authors:  J S Baumstark; C T Lee; R J Luby
Journal:  Biochim Biophys Acta       Date:  1977-06-10

8.  Interaction of human alpha-1-antitrypsin with porcine trypsin.

Authors:  A B Cohen; D Geczy; H L James
Journal:  Biochemistry       Date:  1978-02-07       Impact factor: 3.162

9.  Platelet elastase and leukocyte elastase are two different entities.

Authors:  Y Legrand; J P Caen; L Robert; J L Wautier
Journal:  Thromb Haemost       Date:  1977-06-30       Impact factor: 5.249

10.  The interaction of alpha-1-antitrypsin with soluble and sepharose-bound elastase.

Authors:  T N Lo; A B Cohen; H L James
Journal:  Biochim Biophys Acta       Date:  1976-12-22
View more
  9 in total

1.  Expression and Purification of Active Recombinant Human Alpha-1 Antitrypsin (AAT) from Escherichia coli.

Authors:  Beena Krishnan; Lizbeth Hedstrom; Daniel N Hebert; Lila M Gierasch; Anne Gershenson
Journal:  Methods Mol Biol       Date:  2017

2.  Protease inhibitors in inflammatory synovial effusions.

Authors:  N M Hadler; A M Johnson; J K Spitznagel; R J Quinet
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

3.  The C-terminal sequence of human and porcine antithrombin III and its homology with human alpha-1-proteinase inhibitor.

Authors:  T Koide; Y Ohta; T Ono
Journal:  Experientia       Date:  1980-05-15

4.  Inhibitory capacity of alpha 1 antitrypsin in lung secretions: variability and the effect of drugs.

Authors:  H M Morrison; S C Afford; R A Stockley
Journal:  Thorax       Date:  1984-07       Impact factor: 9.139

5.  A unique elastase in human blood platelets.

Authors:  H L James; Y T Wachtfogel; P L James; M Zimmerman; R W Colman; A B Cohen
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

6.  Oxidative regulation of neutrophil elastase-alpha-1-proteinase inhibitor interactions.

Authors:  P J Ossanna; S T Test; N R Matheson; S Regiani; S J Weiss
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

7.  Synovial protease/inhibitor ratios in erosive and nonerosive arthropathies.

Authors:  M H Pritchard
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

8.  Genetic heterogeneity of rabbit alpha-1-antitrypsin.

Authors:  F Kueppers; C C Lee; R R Fox; J K Mills
Journal:  Genetics       Date:  1984-04       Impact factor: 4.562

9.  Degradation in vivo of articular cartilage in rheumatoid arthritis and juvenile chronic arthritis by cathepsin G and elastase from polymorphonuclear leukocytes.

Authors:  M Velvart; K Fehr
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.